Stocks Health care CTMX
NASDAQ · Health careCytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. brought in $18.3M of revenue over the twelve months to June 30, 2026, down 87.0% from a year earlier. It posted a net loss of $79.7M. In fiscal 2025 capital spending exceeded operating cash flow by $75.8M. At June 30, 2026 it held $17.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What CytomX Therapeutics, Inc. does
CytomX Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTMX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $76.2M | -$17.4M | n/a | -$75.8M |
| 2024 | $138.1M | $31.9M | n/a | -$86.5M |
| 2023 | $101.2M | -$569K | n/a | -$56.9M |
| 2022 | $53.2M | -$99.3M | n/a | -$112.5M |
| 2021 | $37.3M | -$115.9M | n/a | -$120.6M |
| 2020 | $68.4M | -$64.8M | n/a | $3M |
Latest SEC filings
What CytomX Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 3, 2026Passive stake (5% or more) SCHEDULE 13G
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- July 27, 2026
- June 22, 2026
Questions about CTMX
What does CytomX Therapeutics, Inc. do?
CytomX Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTMX.
Is CytomX Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $79.7M on revenue of $18.3M.
How much revenue does CytomX Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 CytomX Therapeutics, Inc. reported revenue of $18.3M. That is 87.0% less than a year earlier.
When did CytomX Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.
Similar companies
Follow CTMX
Get an email when CytomX Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CTMX: get an email when it filesWhere the numbers come from
Financial figures are the values CytomX Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.